GlassScriptPhysician profile
Marc H Brickman
NPI 1437101789
$2,591.87
in general payments reported to CMS, 2019-2025
37 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $252 · 2021: $134 · 2022: $167 · 2023: $924 · 2024: $597 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $443.51 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $272.49 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $199.87 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $166.55 | 2019-2023 | |
| Amgen INC. | $162.69 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $153.53 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $148.26 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $86.23 | 2022-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $83.50 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.11 | 2020-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $75.83 | 2022-2025 | |
| Exact Sciences Corporation | $71.92 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $65.05 | 2022-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $57.14 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $54.76 | 2022-2023 | Rexulti |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicure Pharma INC. | $46.36 | 2021 | |
| Antares Pharma, INC. | $44.37 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Xeris Pharmaceuticals, INC. | $44.34 | 2023 | Gvoke Hypopen |
| Insulet Corporation | $35.66 | 2023 | Omnipod |
| Idorsia Pharmaceuticals US INC | $30.85 | 2023 | Quviviq |
| Amarin Pharma, INC. | $25.60 | 2020-2021 | |
| Abbott Laboratories | $21.21 | 2024 | |
| Cook Medical LLC | $18.21 | 2025 | Zenith Spiral-Z |
| Stryker Corporation | $17.46 | 2025 | Clottriever Bold Catheter |
| Esperion Therapeutics, INC. | $17.07 | 2020 | |
| Amag Pharmaceuticals, INC. | $16.99 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.43 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.20 | 2022 | |
| Ge Healthcare | $14.65 | 2020 | |
| Janssen Biotech, INC. | $14.55 | 2019 | |
| Daiichi Sankyo INC. | $14.32 | 2020 | |
| Tolmar, INC. | $13.99 | 2024 | |
| Halozyme INC | $13.73 | 2023 | |
| Scilex Pharmaceuticals INC. | $12.92 | 2019 | |
| Boston Scientific Corporation | $11.98 | 2019 | |
| Endogastric Solutions, INC | $11.62 | 2023 | Esophyx |
| Kowa Pharmaceuticals America, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Brickman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.